Tag Archives: NASDAQ:AVXL

Anavex Life Sciences Corp (NASDAQ:AVXL), the clinical stage biopharmaceutical developing treatments for neurodegenerative and neurodevelopmental diseases, has been recently under the radar of many institutional investors. We assessed the company...

While the shorts continue their in-vein efforts to beat down on Anavex Life Sciences Corp. (NASDAQ:AVXL), the company continues to hold it’s own in the markets. At last count, Anavex traded for a little over $5.82 (pre market on Tuesday),...

Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the companies that we have repeatedly pitched as having a bright future, against a backdrop of our competitors over at The Street and Fool repeatedly painting the company as a sure thing short....

For the last eighteen months, Anavex Life Sciences Corp. (NASDAQ:AVXL) has been at the the center of a great debate. From the company falling foul of an army of short sellers, to management overpaying themselves, to the science being made up,...

There’s been a lot of chatter over the deal between Anavex Life Sciences Corp (NASDAQ:AVXL) and Biogen Inc (NASDAQ:BIIB). Most of it coming from short sellers and the hacks that call themselves experts over at our competitors The Street...

The date July 27, 2016 will be one which almost every trader and investor in Anavex Life Sciences Corp (NASDAQ:AVXL) will remember. While the bears may have won the battle that day, they still have not won the war. Might of fact, they’ve...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter